Genes & biomarkers
BCR::ABL1 fusion
BCR::ABL1 · Philadelphia chromosome · Ph+
A fusion important for targeted treatment and molecular monitoring in CML and related settings.
Sources checked · Introductory guide
On this page
What does this result mean?
An exchange between chromosomes 9 and 22 can join BCR and ABL1. The resulting Philadelphia chromosome is characteristic of CML. This acquired change is generally not passed to children.[1]
How does it connect to treatment?
ABL tyrosine kinase inhibitors such as imatinib or dasatinib are used in CML and selected Ph-positive ALL. Disease, phase, prior drugs and response guide the drug and any combination.[2]
What should I check in my report?
Initial positivity and the change in BCR::ABL1 levels during treatment are different information. Ask about quantitative PCR monitoring and comparison standards; do not stop medication based on one result alone.
Questions for your care team
- How does my BCR::ABL1 level compare with earlier results, and when is the next test?
- Which treatments or trials fit my cancer type, stage and previous treatment?
Sources and scope
Source documents are in English.
Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.
- MedlinePlus Genetics · Chronic myeloid leukemia (opens in a new tab)
- NCI · Dasatinib (opens in a new tab)
- NCI · Chronic Myeloid Leukemia Treatment (PDQ) (opens in a new tab)
General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.